Literature DB >> 15961522

Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis.

A Jacoby1, A Rannard, D Buck, N Bhala, J L Newton, O F W James, D E J Jones.   

Abstract

BACKGROUND AND AIMS: Study of health related quality of life (HRQOL) and the factors responsible for its impairment in primary biliary cirrhosis (PBC) has, to date, been limited. There is increasing need for a HRQOL questionnaire which is specific to PBC. The aim of this study was to develop, validate, and evaluate a patient based PBC specific HRQOL measure. SUBJECTS AND METHODS: A pool of potential questions was derived from thematic analysis of indepth interviews carried out with 30 PBC patients selected to represent demographically the PBC patient population as a whole. This pool was systematically reduced, pretested, and cross validated with other HRQOL measures in national surveys involving a total of 900 PBC patients, to produce a quality of life profile measure, the PBC-40, consisting of 40 questions distributed across six domains. The PBC-40 was then evaluated in a blinded comparison with other HRQOL measures in a further cohort of 40 PBC patients.
RESULTS: The six domains of PBC-40 relate to fatigue, emotional, social, and cognitive function, general symptoms, and itch. The highest mean domain score was seen for fatigue and the lowest for itch. The measure has been fully validated for use in PBC and shown to be scientifically sound. PBC patient satisfaction, measured in terms of the extent to which a questionnaire addresses the problems that they experience, was significantly higher for the PBC-40 than for other HRQOL measures.
CONCLUSION: The PBC-40 is a short easy to complete measure which is acceptable to PBC patients and has significantly greater relevance to their problems than other frequently used HRQOL measures. Its scientific soundness, shown in extensive testing, makes it a valuable instrument for future use in clinical and research settings.

Entities:  

Mesh:

Year:  2005        PMID: 15961522      PMCID: PMC1774759          DOI: 10.1136/gut.2005.065862

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  29 in total

Review 1.  Are quality of life measures patient centred?

Authors:  A J Carr; I J Higginson
Journal:  BMJ       Date:  2001-06-02

2.  Assessing quality of life in primary biliary cirrhosis.

Authors:  Anne Rannard; Deborah Buck; David E J Jones; Oliver F W James; Ann Jacoby
Journal:  Clin Gastroenterol Hepatol       Date:  2004-02       Impact factor: 11.382

Review 3.  Generic and disease-specific measures in assessing health status and quality of life.

Authors:  D L Patrick; R A Deyo
Journal:  Med Care       Date:  1989-03       Impact factor: 2.983

4.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

5.  The rights of patients in research.

Authors:  H Goodare; R Smith
Journal:  BMJ       Date:  1995-05-20

6.  Health status, quality of life, and the individual.

Authors:  G H Guyatt; D J Cook
Journal:  JAMA       Date:  1994 Aug 24-31       Impact factor: 56.272

7.  The true impact of fatigue in primary biliary cirrhosis: a population study.

Authors:  Jennifer Goldblatt; Philip J S Taylor; Toby Lipman; Martin I Prince; Anna Baragiotta; Margaret F Bassendine; Oliver F W James; David E J Jones
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

8.  The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups.

Authors:  C A McHorney; J E Ware; J F Lu; C D Sherbourne
Journal:  Med Care       Date:  1994-01       Impact factor: 2.983

9.  A procedure for developing a quality-of-life measure for epilepsy surgery patients.

Authors:  B G Vickrey
Journal:  Epilepsia       Date:  1993       Impact factor: 5.864

10.  Quality of life in patients with primary biliary cirrhosis.

Authors:  Renée Eugénie Poupon; Yves Chrétien; Olivier Chazouillères; Raoul Poupon; Judith Chwalow
Journal:  Hepatology       Date:  2004-08       Impact factor: 17.425

View more
  57 in total

Review 1.  Fatigue in primary biliary cirrhosis.

Authors:  Ghulam Abbas; Roberta A Jorgensen; Keith D Lindor
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-05-11       Impact factor: 46.802

2.  Randomized clinical trial: Combination antiretroviral therapy with tenofovir-emtricitabine and lopinavir-ritonavir in patients with primary biliary cholangitis.

Authors:  Ellina Lytvyak; Ishwar Hosamani; Aldo J Montano-Loza; Lynora Saxinger; Andrew L Mason
Journal:  Can Liver J       Date:  2019-01-09

3.  Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort.

Authors:  D E J Jones; N Bhala; J Burt; J Goldblatt; M Prince; J L Newton
Journal:  Gut       Date:  2005-11-18       Impact factor: 23.059

4.  PBC: Better Solutions to Beat Feeling Beat.

Authors:  Naw April Phaw; David E J Jones
Journal:  Dig Dis Sci       Date:  2019-08       Impact factor: 3.199

5.  Thyroid Dysfunction in Primary Biliary Cholangitis: A Comparative Study at Two European Centers.

Authors:  Annarosa Floreani; Chiara Mangini; Anna Reig; Irene Franceschet; Nora Cazzagon; Lisa Perini; Llorenç Caballería; Silvia Cocchio; Vincenzo Baldo; Albert Parés
Journal:  Am J Gastroenterol       Date:  2016-10-25       Impact factor: 10.864

6.  The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.

Authors:  Gideon M Hirschfield; Jessica K Dyson; Graeme J M Alexander; Michael H Chapman; Jane Collier; Stefan Hübscher; Imran Patanwala; Stephen P Pereira; Collette Thain; Douglas Thorburn; Dina Tiniakos; Martine Walmsley; George Webster; David E J Jones
Journal:  Gut       Date:  2018-03-28       Impact factor: 23.059

7.  Treatment of Fatigue in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis.

Authors:  Jennifer Y Lee; Christopher J Danford; Hirsh D Trivedi; Elliot B Tapper; Vilas R Patwardhan; Alan Bonder
Journal:  Dig Dis Sci       Date:  2019-01-10       Impact factor: 3.199

8.  Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study.

Authors:  Minami Yagi; Atsushi Tanaka; Tadashi Namisaki; Atsushi Takahashi; Masanori Abe; Akira Honda; Yasushi Matsuzaki; Hiromasa Ohira; Hitoshi Yoshiji; Hajime Takikawa
Journal:  J Gastroenterol       Date:  2018-04-16       Impact factor: 7.527

9.  Factors that Influence Health-Related Quality of Life in Patients with Primary Sclerosing Cholangitis.

Authors:  Angela C Cheung; Harshna Patel; Javier Meza-Cardona; Maria Cino; Sanjeev Sockalingam; Gideon M Hirschfield
Journal:  Dig Dis Sci       Date:  2016-01-07       Impact factor: 3.199

10.  Quality of life and everyday activities in patients with primary biliary cirrhosis.

Authors:  Carlo Selmi; M Eric Gershwin; Keith D Lindor; Howard J Worman; Ellen B Gold; Mitchell Watnik; Jessica Utts; Pietro Invernizzi; Marshall M Kaplan; John M Vierling; Christopher L Bowlus; Marina G Silveira; Ilaria Bossi
Journal:  Hepatology       Date:  2007-12       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.